Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study - PubMed
8 days ago
- #relapse treatment
- #multiple myeloma
- #bispecific antibodies
- Idecabtagene vicleucel (ide-cel) shows high response rates in relapsed/refractory multiple myeloma but all patients eventually relapse.
- A real-world French study of 154 patients relapsing after ide-cel found a median time to progression of 6.0 months.
- Salvage therapies included anti-BCMA bispecific antibodies (BsAbs), non-BCMA BsAbs, and combinations of other treatments.
- Median overall survival was 12.12 months and progression-free survival was 3.48 months.
- Non-BCMA BsAbs showed significantly higher response rates, overall survival, and progression-free survival compared to anti-BCMA BsAbs.
- Early relapse (≤6 months), extramedullary disease, and prior exposure to >3 lines of therapy were associated with worse outcomes.
- Anti-BCMA BsAbs had limited efficacy, while non-BCMA BsAbs may be a promising approach post-ide-cel relapse.
- The study highlights the need for diversifying targets in relapse treatment strategies post-ide-cel.